Bandyopadhyay Prabirkumar
Sandwell Medical Research Unit, Sandwell and West Birmingham Hospitals NHS Trust, Lyndon, West Bromwich, West Midlands, B71 4HJ, UK.
Drug News Perspect. 2009 Nov;22(9):559-67. doi: 10.1358/dnp.2009.22.9.1434633.
Type 2 diabetes (T2D) is associated with a greatly increased risk of cardiovascular disease. An increasing need for glucose-lowering treatments is emphasized by the almost inevitable failure of monotherapy and occurrence of weight gain. Recently, novel classes of drugs derived from the incretin system have been introduced into the management of T2D. Recent advances in the field of incretin-based therapies in the management of T2D were discussed at the 45th Annual Meeting of the European Association for the Study of Diabetes, held from September 29 until October 2, 2009, in Vienna, Austria.
2型糖尿病（T2D）与心血管疾病风险大幅增加相关。单药治疗几乎不可避免的失败以及体重增加的发生凸显了对降糖治疗的需求日益增加。最近，源自肠促胰岛素系统的新型药物已被引入到2型糖尿病的管理中。2009年9月29日至10月2日在奥地利维也纳举行的第45届欧洲糖尿病研究协会年会上讨论了基于肠促胰岛素疗法在2型糖尿病管理领域的最新进展。
